Author: Li Tan; Xia Kang; Bo Zhang; Shangen Zheng; Bo Liu; Tiantian Yu; Fan Yang; Qiongshu Wang; Hongming Miao
Title: A special case of COVID-19 with long duration of viral shedding for 49 days Document date: 2020_3_27
ID: jzosdlu7_46
Snippet: Besides to the long duration, several points should also be concerned. Firstly, the virus infecting this family cluster case appeared low toxicity and low transmissibility. However, it also showed a prolonged infective ability and was hardly to be eliminated in body. This virus type may exist in human bodies for a long time and may be a risk to contribute to periodic outbreak in future considering the high mutation in COVID-19. Secondly, a rapidl.....
Document: Besides to the long duration, several points should also be concerned. Firstly, the virus infecting this family cluster case appeared low toxicity and low transmissibility. However, it also showed a prolonged infective ability and was hardly to be eliminated in body. This virus type may exist in human bodies for a long time and may be a risk to contribute to periodic outbreak in future considering the high mutation in COVID-19. Secondly, a rapidly controlled fever with normal level of immune cells may be a good predictor to identify patients with superior outcomes in early stage. This conclusion is needed to be validated in carefully designed clinical studies. Thirdly, plasma infusion could be an efficient therapy for patients with COVID-19. Last, long term health status and the infective ability of these people are needed to be followed up due to prolonged infection. Our report provides valuable information for public health management and for the decision making in triage and long-term . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Moderate-cured, Moderate type of cases with a cured outcome; IL-6, interleukin-6; PCT, procalcitonin . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
Search related documents:
Co phrase search for related documents- carefully design and clinical study: 1
- case moderate type and clinical study: 1
- cc NC ND International license and clinical study: 1, 2, 3, 4, 5, 6, 7
- cc NC ND International license and early stage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- cc NC ND International license and family cluster: 1, 2
- cc NC ND International license and family cluster case: 1, 2
- cc NC ND International license and health status: 1, 2, 3, 4
- clinical study and cure outcome: 1
- clinical study and early stage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical study and efficient therapy: 1, 2, 3
- clinical study and family cluster: 1, 2, 3, 4, 5, 6, 7, 8, 9
- clinical study and good predictor: 1, 2, 3
- clinical study and health status: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical study and high mutation: 1
- early stage and efficient therapy: 1, 2
- early stage and family cluster: 1, 2, 3, 4, 5, 6
- early stage and good predictor: 1, 2
- early stage and health status: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- early stage and high mutation: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date